RDHL Stock Overview
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
RedHill Biopharma Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.46 |
| 52 Week High | US$3.28 |
| 52 Week Low | US$0.26 |
| Beta | 3.45 |
| 1 Month Change | 7.45% |
| 3 Month Change | -17.94% |
| 1 Year Change | -78.98% |
| 3 Year Change | -99.83% |
| 5 Year Change | -99.85% |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
RedHill Biopharma Ltd. (NASDAQ:RDHL) Might Not Be As Mispriced As It Looks
Jul 28
One RedHill Biopharma Ltd. (NASDAQ:RDHL) Analyst Has Been Cutting Their Forecasts
Nov 24RedHill Biopharma receives Nasdaq notification regarding minimum bid price deficiency
Oct 18RedHill wins EU’s orphan drug status to RHB-204 for rare lung disease
Aug 17RedHill: Given Up For Dead
Apr 30RedHill Biopharma: Looking At An Unexciting Dead-End
Dec 30RedHill Biopharma Ltd. (NASDAQ:RDHL) Just Reported, And Analysts Assigned A US$15.79 Price Target
Dec 02Shareholder Returns
| RDHL | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.4% | -0.1% | 1.0% |
| 1Y | -79.0% | 13.6% | 27.2% |
Return vs Industry: RDHL underperformed the US Pharmaceuticals industry which returned 13.1% over the past year.
Return vs Market: RDHL underperformed the US Market which returned 25.7% over the past year.
Price Volatility
| RDHL volatility | |
|---|---|
| RDHL Average Weekly Movement | 9.1% |
| Pharmaceuticals Industry Average Movement | 10.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: RDHL's share price has been volatile over the past 3 months.
Volatility Over Time: RDHL's weekly volatility has decreased from 40% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 53 | Dror Ben-Asher | www.redhillbio.com |
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers’ diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn’s disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.
RedHill Biopharma Ltd. Fundamentals Summary
| RDHL fundamental statistics | |
|---|---|
| Market cap | US$14.78m |
| Earnings (TTM) | US$23.92m |
| Revenue (TTM) | US$6.53m |
0.6x
P/E Ratio2.2x
P/S RatioIs RDHL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RDHL income statement (TTM) | |
|---|---|
| Revenue | US$6.53m |
| Cost of Revenue | US$3.46m |
| Gross Profit | US$3.07m |
| Other Expenses | -US$20.84m |
| Earnings | US$23.92m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.75 |
| Gross Margin | 47.03% |
| Net Profit Margin | 366.25% |
| Debt/Equity Ratio | 0% |
How did RDHL perform over the long term?
See historical performance and comparison